In fact, semaglutide is approved by the US FDA for use in chronic weight management in adults with a body mass index (BMI) of 30 or greater or in those with a BMI of 27 or greater and at least one weight-related condition
These changes happen alongside weight loss and contribute to overall health benefits
Studies show that about 25% of people with overweight who lose weight through conventional methods are able to maintain that loss ( Those who regain their lost weight are more likely to seek solutions such as dietary supplements and herbal medicines
Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryden L, et al
These are found in fatty fish (salmon), olive oil, avocados, raw nuts and seeds
Therefore, the research and development of the relevant drugs and the replacement therapy of double GIP-GLP-1R agonists (e.g., tirzepatide) and triple GIP-GCG-GLP-1R (e.g., peptide 20) agonist are key research fields